Feb 6 (Reuters) - Alumis Inc ( ALMS ):

* ALUMIS AND ACELYRIN TO MERGE CREATING A LATE-STAGE

CLINICAL

BIOPHARMA COMPANY DEDICATED TO INNOVATING, DEVELOPING AND

COMMERCIALIZING TRANSFORMATIVE THERAPIES FOR IMMUNE-MEDIATED

DISEASES

* ALUMIS INC ( ALMS ): ALUMIS ( ALMS ) & ACELYRIN STOCKHOLDERS TO OWN ABOUT

55% &

ABOUT 45%, RESPECTIVELY, OF COMBINED CO ON FULLY DILUTED BASIS

* ALUMIS INC ( ALMS ): COMBINED COMPANY WILL OPERATE UNDER ALUMIS

NAME WITH

CURRENT ALUMIS EXECUTIVE TEAM

* ALUMIS INC ( ALMS ): UNDER DEAL, ACELYRIN STOCKHOLDERS TO RECEIVE

0.4274

SHARES OF ALUMIS COMMON STOCK FOR EACH SHARE OF ACELYRIN COMMON

STOCK OWNED

* ALUMIS INC ( ALMS ): ALUMIS ( ALMS ) & ACELYRIN'S ( SLRN ) COMBINED PRO FORMA CASH

POSITION

OF ABOUT $737 MILLION AS OF DEC 31, 2024, PROVIDES RUNWAY INTO

2027

Source text:

Further company coverage: